Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine Inc. has entered a development agreement with Polyrizon Ltd. to create an intranasal formulation of its proprietary, non-hallucinogenic neuroplastogen MEAI. The goal is to enhance drug delivery and support ongoing and future clinical programs targeting addiction-related and other central nervous system disorders.
The collaboration combines Clearmind’s neuroplastogen expertise with Polyrizon’s intranasal hydrogel technology to potentially improve bioavailability, therapeutic effect and patient experience. Polyrizon is a related party under Canadian securities rules, and Clearmind is relying on available exemptions from formal valuation and minority shareholder approval for this related party transaction.
Clearmind Medicine Inc. is drawing additional funding under previously agreed convertible note financing. The company will issue and sell convertible promissory notes with an aggregate principal amount of $2,500,000, for a cash purchase price equal to 90% of principal, or $2,250,000.
The first tranche closed on February 4, 2026 with $600,000 principal for $540,000 in cash. A second tranche of $1,900,000 principal for $1,710,000 in cash will close after Clearmind files a registration statement covering resale of the common shares issuable upon conversion of the notes.
Clearmind Medicine reports that its proprietary compound MEAI (5-MeO-AI), a next-generation, non-hallucinogenic neuroplastogen, has been specifically named in new bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).
The bill would direct the U.S. Department of Veterans Affairs to create investigational research and extended access treatment programs using emerging therapies for unmet medical needs in veterans. Covered therapies include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine and others designated by the VA Secretary.
This is the first time MEAI has been referenced in U.S. federal legislation. Clearmind highlights potential applications for conditions such as Alcohol Use Disorder and post-traumatic stress disorder, emphasizing growing policy recognition of innovative, evidence-based psychedelic and neuroplastogen approaches.
Clearmind Medicine Inc. is updating its registration to cover the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are held by institutional selling shareholders from a January 2024 private placement and prior related financings, and represent a significant portion of the company’s 1,499,838 common shares outstanding as of January 26, 2026.
The company will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if all related warrants are exercised for cash at their current exercise price. A risk factor highlights that resale of these shares, equal to about 22.13% of outstanding shares as of January 26, 2026, could pressure the market price, and notes additional geopolitical risks tied to Clearmind’s operations and personnel presence in Israel.
Clearmind Medicine Inc. filed a post-effective amendment that updates prior registration statements covering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are being registered for selling shareholders from a January 2024 private placement and may be sold from time to time on Nasdaq or in negotiated deals. Clearmind will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if the PIPE warrants are fully exercised for cash. As of January 26, 2026, Clearmind had 1,499,838 common shares outstanding, and full exercise of the registered PIPE warrants would increase this to 1,831,787 shares. The filing notes that the 331,949 warrant shares equal about 22.13% of common shares outstanding before this offering, highlighting potential resale overhang for existing shareholders.
Clearmind Medicine Inc. is updating a prior registration and converting it to a Form F-3 to allow the resale of up to 296,130 common shares by existing holders. These shares include 294,969 shares tied to convertible promissory notes and 1,161 shares granted as equity awards. Clearmind has already issued promissory notes with an aggregate principal of $2.5 million, all of which, plus accrued interest, have been converted into 129,287 common shares as of January 26, 2026. The notes convert at the lower of a fixed price of $40.40 or 88% of recent VWAP, but not below a floor of $8.00. Clearmind will not sell any shares in this resale and will not receive proceeds from selling shareholders, though it may receive up to an additional $6.75 million in gross proceeds if it elects to issue more notes under the purchase agreements. Shares outstanding were 1,499,838 as of January 26, 2026, and would be 1,795,968 if all registered note shares are issued.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company focused on psychedelic-based therapies, files its annual Form 20-F reporting continued operating losses and substantial going concern uncertainty. The company recorded operating losses of $5,667,177, $5,744,925 and $6,303,434 for the years ended October 31, 2025, 2024 and 2023, with net losses of $3,856,983, $5,254,678 and $8,620,837, and an accumulated deficit of $27,879,724 as of October 31, 2025.
The auditors include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, noting negative operating cash flows of $4,734,498 and reliance on future equity or debt financing. Clearmind reports cash and cash equivalents of $3,923,058 as of October 31, 2025 and remains pre-revenue with no approved products, advancing lead candidate MEAI through early-stage clinical development for alcohol use disorder and other indications under significant regulatory, clinical, funding and commercialization risks.